Our Organisation

Illumina is a global leader in DNA sequencing and array-based technologies. For 25 years, Illumina’s innovations have fuelled advancements in life sciences, oncology, reproductive health, genetic disease, agriculture, microbiology, and other emerging segments. Headquartered in San Diego, California, Illumina is listed on the NASDAQ with global revenues of $4.6bn and more than 10,000 employees worldwide.

Mark has been the General Manager for the UK & Ireland and Northern Europe since 2023. In this role, he leads the commercial business in these strategically important geographies, designing the strategy, setting the goals for growth and managing the day-to-day operations. Mark has overall responsibility for the key relationships in these regions, including those with government, healthcare systems and key strategic partners. Additionally, he has oversight of all of Illumina’s operations in the UK, including site leadership of Illumina’s European hub in Cambridge.

Mark joined Illumina as its EMEA CFO in November 2019 and in March 2021 became responsible for its broader international business, covering the EMEA, Asia Pacific and China regions with revenues of circa $1.5bn. In this role, Mark led the finance function across the 3 regions and overseeing accounting, financial shared services, tax and FP&A; whilst playing a significant role in the strategic leadership of the business.

Prior to joining Illumina, Mark has a strong track record within healthcare; spending 13 years at Johnson & Johnson in various senior finance roles across the Medical Device and Consumer sectors and, before that, 5 years at Pfizer in their Pharmaceutical and Consumer Health divisions. Mark is a chartered management accountant and holds an economics degree from the University of Exeter.